Related Experiment Videos
Intravenous rtPA thrombolysis in acute ischemic stroke
1Department of Neurology, Mont-Godinne University Hospital, Université Catholique de Louvain, Yvoir, Belgium.
Acta Neurologica Belgica
|August 7, 2001
Summary
Intravenous thrombolysis with alteplase (tPA) is effective for acute ischemic stroke within 3 hours. However, its use between 3-6 hours remains controversial, requiring careful patient selection and advanced imaging like MRI.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Radiology
Background:
- Acute ischemic stroke treatment has evolved, with early intravenous thrombolysis being a cornerstone therapy.
- Intravenous alteplase (tPA) is the first approved treatment, but its efficacy and safety profile, particularly regarding intracranial hemorrhage, necessitate careful consideration.
- Not all patients benefit from tPA, and the therapeutic window remains a subject of ongoing research.
Purpose of the Study:
- To provide an overview of the efficacy and safety of intravenous alteplase (tPA) in acute cerebral ischemia.
- To discuss the rationale, limitations, and optimal application of thrombolytic therapy in stroke.
- To evaluate the potential of advanced imaging techniques in patient selection for thrombolysis.
Main Methods:
- Review of controlled studies on intravenous tPA in acute ischemic stroke.
- Analysis of data regarding functional outcomes and risk of intracranial hemorrhage.
- Discussion of the role of MRI (diffusion- and perfusion-weighted sequences, MR-angiography) versus CT scan for patient selection.
- Assessment of tPA applicability in current neurological practice, specifically in Belgium.
Main Results:
- Intravenous tPA is effective and safe within the first 3 hours post-stroke onset under restrictive conditions.
- Efficacy and safety data for the extended therapeutic window (3-6 hours) are controversial and require further investigation.
- Patient selection based on specific clinical and imaging criteria is crucial for optimizing functional improvement and minimizing hemorrhage risk.
- MRI techniques are suggested to be superior to CT for patient selection in the future.
Conclusions:
- Thrombolytic therapy with tPA is a valuable treatment for acute ischemic stroke, but its application must be guided by strict criteria.
- The 3-6 hour time window requires further research to establish clear guidelines for tPA administration.
- Advanced neuroimaging, particularly MRI, holds promise for improving patient selection and treatment outcomes.
- Widespread implementation of tPA therapy should be preceded by restriction to specialized stroke centers and mandatory data recording for continuous surveillance.